Additive/synergistic: In vitro: EZH2 knock-down increased sensitivity to cisplatin. In vivo: EZH2 knockdown combined with cisplatin led to greater reduction of tumor growth than cisplatin alone. The gene discussed is EZH2; the disease is neoplasm.